This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Do you, or did you, own shares of Vanda Pharmaceuticals Inc. (NASDAQ GM: VNDA)?
Did you purchase your shares before December 18, 2012, or between December 18, 2012 and June 18, 2013?
Did you lose money in your investment in Vanda Pharmaceuticals Inc.?
Do you want to discuss your rights?
Rigrodsky & Long, P.A., including former Special Assistant United States Attorney, Timothy J. MacFall, announces that a complaint has been filed in the United States District Court for the District of Columbia on behalf of all persons or entities that purchased the common stock of Vanda Pharmaceuticals Inc. (“Vanda” or the “Company”) (NASDAQ GM:
VNDA) between December 18, 2012 and June 18, 2013, inclusive (the “Class Period”), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the “Complaint”).
If you purchased shares of Vanda during the Class Period, or purchased shares prior to the Class Period and still hold Vanda, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact
Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 825 East Gate Boulevard, Suite 300, Garden City, NY at (888) 969-4242, by e-mail to
email@example.com, or at:
Vanda is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous systems disorders. The Company’s product portfolio includes tasimelteon, a compound for the treatment of circadian rhythm sleep disorders (CRSD), which is currently in clinical development for “Non-24,” a serious, rare CRSD that affects a majority of totally blind individuals. The Complaint alleges that throughout the Class Period, defendants made materially false and misleading statements, and omitted materially adverse facts, about the Company’s business, operations and prospects. Specifically, the Complaint alleges that the defendants concealed from the investing public that: (1) the Company was forced to unilaterally change the primary endpoint in the middle of Phase III studies as it was already in possession of data suggesting that the original primary endpoint was not going to be met; (2) the Company eliminated nighttime total sleep as the primary endpoint in its studies as there was no discernible difference in efficacy and safety in nighttime total sleep between those patients deemed to have Non-24 and those patients with a normal circadian rhythm; (3) the replacement primary endpoint installed to assess tasimelteon’s efficacy and safety was created
ex ante by the Company and has never been used before in sleep-drug clinical trials, nor was it endorsed by the U.S. Food and Drug Administration (“FDA”); and (4) as a result of the foregoing, the Company’s statements were materially false and misleading at all relevant times. As a result of defendants’ false and misleading statements, the Company’s stock traded at artificially inflated prices during the Class Period.
According to the Complaint, on June 19, 2013,
The Street published an article raising doubts about the quality and efficacy of Vanda’s clinical trial procedure and test data. Among other issues, the article noted multiple changes in the primary endpoint over the course of the trials, including a change just one month before study results were published to a new primary endpoint that has allegedly never been used before in sleep-drug clinical trials, nor was it endorsed by the FDA. The article also states that Vanda was forced to cut patient enrollment in the clinical trials in half because an insufficient number of totally blind patients with Non-24 could not be identified, and that ultimately less that 5% of the patients enrolled in the trials suffered from Non-24 according to the “textbook definition” of the disease.
On these revelations, shares in Vanda dropped more than 22%, closing at $8.51 per share on June 19, 2013, from a close of $10.92 per share on June 18, 2013, on heavy trading volume of over 8 million shares.